Biotech Values

[DewDiligence]

MNTA – This is Sanofi’s official 2009 guidance:

http://finance.yahoo.com/news/Sanofiaventis-Delivers-2008-prnews-14321033.html

In 2009, sanofi-aventis expects growth in adjusted EPS excluding selected items of at least 7% at constant exchange rates, barring major adverse events such as the launch of a generic of Lovenox in the United States.

As previously noted on this board, if MNTA/Sandoz obtain the only FDA-approved generic for Lovenox, it will be the largest-selling generic drug of all time by a wide margin and clearly a “major adverse event” for Sanofi!